ICNC Abstracts, ICNC 2018

Font Size: 
Clinical and prognostic analysis of ocular myasthenia gravis in children
Chen Jiji, Jiang Li, Li Xiujuan, Hong Siqi

Last modified: 2018-09-09

Abstract


Objective: To explore the clinical features, therapeutic effects and prognostic factors of ocular myasthenia gravis(OMG) in children. Methods: Collected the the clinical data of OMG in 220 children. Result:1. In 220 children of OMG, the average age of onset was 3.67±3.06 years. 2. At onset, 199 cases had ptosis, 20 cases had ptosis and diplopia, and 1 case only had diplopia. 3. The positive rate of the Neostigmine test, Repetitive Neuroelectric Stimulation, myasthenia gravis related antibody, thyroid function, and autoantibody was 98.18%, 24.43%, 39.13%, 16.58%, and 13.71%, and the abnormal rate of thymus was only 1.02%. 4. The remission rate was 49.09% in 110 patients treated with pyridostigmine bromide, and can reach 77.27% after added with glucocorticoid or/and IVIG. 62 patients were treated with pyridostigmine bromide and glucorticosteroid, and the remission rate was 83.87%. There were no differences in the efficacy of three groups of different glucorticosteroids treatment(p>0.05). 5. Only 4 cases developed into GMG, of which 2 cases had myasthenia crisis. 6.The prognosis of OMG had a significant correlation with repeated neuroelectric stimulation(p<0.05). Conclusion: 1. Ptosis and diplopia are mostly found in children with OMG. 2. Children with OMG could combined with other autoimmune diseases, fewer with thymus abnormality. 3. Cholinesterase inhibitors could be used at first in OMG, glucocorticoid and/or IVIG should be used when symptoms are not relieved. 4.The proportion of OMG developed into GMG is low. 5. The abnormal rate of repetitive neuroelectric stimulation may have an impact role on the prognosis of OMG.


Keywords


Ocular myasthenia gravis; Pyridostigmine Bromide;Glucocorticoid;Prognosis

Conference registration is required in order to view papers.